Online Only Articles

Competing risk survival analysis in patients with symptomatic Waldenström macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy

Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece
Hematology Section of the First Department of Propedeutic Internal Medicine, Laikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Greece
Service D’Hématologie Clinique et Thérapie Cellulaire CHU (University Hospital), Amiens, France
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece
Theagenion Cancer Center, Department of Hematology, Thessaloniki, Greece
University of Patras, Hematology Division, Patras, Greece
University of Ioannina, Hematology Division, Ioannina, Greece
Peripheral General Anticancer Hospital-Metaxa, Department of Hematology, Piraeus, Greece
Evangelismos Hospital, Hematology Department, Athens, Attica, Greece
St Savvas Oncology Hospital, Hematology Division, Athens, Greece
G.Gennimatas General Hospital, Department of Hematology, Athens, Greece
Department of Haematology, Nicosia General Hospital, Cyprus, Greece
Henry Dunant Hospital, Hematology Division, Athens, Greece
Department of Pathophysiology, National And Kapodistrian University of Athens, School of Medicine, Greece
Democritus University of Thrace, Alexandroupolis, Greece
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece
Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Greece
Vol. 100 No. 11 (2015): November, 2015 https://doi.org/10.3324/haematol.2015.124149